# OnCo record nct06452277 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06452277/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06452277", "NCT06452277" ;
  schema:name "A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma"@en ;
  schema:alternateName "SOHO-02"@en ;
  schema:description "A phase 3 trial of Sevabertinib, Pembrolizumab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bayer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06452277/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06452277> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-08-28" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/bayer/> .